The Recall Desk
ModerateFDA (Drugs)·D-0888-2022·Announced 2022-06-01

Zonisamide Capsules USP recalled for quality control system deviation

Direct Rx is recalling Zonisamide Capsules USP 100 mg, lot 23JY2124, nationwide due to gaps in the quality control microbiology laboratory that could affect product verification.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: This is a voluntary precautionary recall triggered by manufacturing quality control system gaps with no reported illnesses, hospitalizations, or confirmed product contamination. FDA Class II classification without evidence of actual harm meets the criteria for Moderate severity.

Plain-English summary

Direct Rx is recalling Zonisamide Capsules USP, 100 mg, 90-count bottles (NDC 61919-775-90) distributed nationwide. The affected lot is 23JY2124, which expires 6/30/23. The product was manufactured for Glenmark Pharmaceuticals Inc., USA.

The recall was initiated due to gaps identified in the quality system within the Quality Control microbiology laboratory. These deficiencies could affect the ability to verify that the product meets required specifications.

Patients currently taking this medication should contact their pharmacist or healthcare provider. No illnesses or adverse events have been reported in connection with this recall.

The recalled product

Product
Zonisamide Capsules USP, 100 mg, 90-count bottle, Rx Only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 61919-775-90
Manufacturer
Direct Rx
Category
Drug
Hazard
  • cgmp-deviation
  • quality-control-deficiency

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • Lot: 23JY2124 Exp. 6/30/23

Distribution

Distributed nationwide across the United States.